bioRxiv · 10.1101/2021.12.11.472236
Isolation and comparative analysis of antibodies that broadly neutralize sarbecoviruses
Abstract
The devastation caused by SARS-CoV-2 has made clear the importance of pandemic preparedness. To address future zoonotic outbreaks due to related viruses in the sarbecovirus subgenus, we identified a human monoclonal antibody, 10-40, that neutralized or bound all sarbecoviruses tested in vitro and protected against SARS-CoV-2 and SARS-CoV in vivo. Comparative studies with other receptor-binding domain (RBD)-directed antibodies showed 10-40 to have the greatest breadth against sarbecoviruses and thus its promise as an agent for pandemic preparedness. Moreover, structural analyses on 10-40 and similar antibodies not only defined an epitope cluster in the inner face of the RBD that is well conserved among sarbecoviruses, but also uncovered a new antibody class with a common CDRH3 motif. Our analyses also suggested that elicitation of this class of antibodies may not be overly difficult, an observation that bodes well for the development of a pan-sarbecovirus vaccine. One sentence summaryA monoclonal antibody that neutralizes or binds all sarbecoviruses tested and represents a reproducible antibody class.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Liu, L., Iketani, S., Guo, Y., Casner, R., Reddem, E., Nair, M. S., Yu, J., Chan, J., Wang, M., Cerutti, G., Li, Z., Castagna, C., Corredor, L., Chu, H., Yuan, S., Poon, V., Chan, C., Chen, Z., Luo, Y., Cunningham, M., Chavez, A., Yin, M., Perlin, D., Tsuji, M., Yuen, K.-Y., Kwong, P., Sheng, Z., Huang, Y., Shapiro, L., Ho, D. D.. 2021-12-14. Isolation and comparative analysis of antibodies that broadly neutralize sarbecoviruses. https://doi.org/10.1101/2021.12.11.472236
Cite the original work for its findings. Save a collection to share your selection of sources.